ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "prognostic factors"

  • Abstract Number: 2913 • 2019 ACR/ARP Annual Meeting

    Serum Interferon Score Predicts Clinical Outcome at 12 Months in Diffuse Cutaneous Systemic Sclerosis as Measured by Global Ranked Composite Score (GRCS) and Composite Response Index in SSc (CRISS)

    Antonio Carriero 1, Giuseppina Abignano 2, MIchelle Hutchinson 3, Karri Ballard 4 and Francesco Del Galdo5, 1University of Leeds, Leeds, England, United Kingdom, 23Rheumatology Institute of Lucania (IReL) and University of Leeds, Leeds, United Kingdom, 3University of Leeds and LTHT NIHR Biomedical Research Centre, Leeds, England, United Kingdom, 4Myriad RBM, austin, TX, 5University of Leeds and LTHT NIHR Biomedical Research Centre, Leeds, United Kingdom

    Background/Purpose: Systemic sclerosis (SSc) is a highly heterogeneous disease orphan of effective disease modifying agents. The diffuse cutaneous clinical subset (dcSSc) is currently targeted in…
  • Abstract Number: 689 • 2019 ACR/ARP Annual Meeting

    Patterns of High Disease Activity Status and Outcomes in Systemic Lupus Erythematosus

    Alberta Hoi 1, Hieu Nim 2, Rachel Koelmeyer 2, Ying Sun 3, Amy Kao 4, Oliver Guenther 3 and Eric Morand2, 1School of Clinical Sciences, Monash University, Meloburne, Victoria, Australia, 2Monash University, Melbourne, Victoria, Australia, 3Merck Healthcare KGaA, Darmstadt, Germany, 4EMD Serono Research & Development Institute, Inc., Billerica, MA

    Background/Purpose: High Disease Activity Status (HDAS), defined as ever attainment of SLEDAI-2k of 10 or greater, may be a useful indicator of overall disease severity in…
  • Abstract Number: 2012 • 2019 ACR/ARP Annual Meeting

    A Composite IFN-Based Signature Is Associated with a Filgotinib-Specific Clinical Response in bDMARD-Experienced Rheumatoid Arthritis Patients

    Peter Taylor1, Bryan Downie 2, Emon Elboudwarej 3, Rachael Hawtin 3, Amer M. Mirza 3 and Jinfeng Liu 3, 1University of Oxford, Oxford, United Kingdom, 2Gilead Sciences, Inc., Foster Citty, CA, 3Gilead Sciences, Inc., Foster City, CA

    Background/Purpose: Filgotinib (FIL), an oral, selective, Janus Kinase 1 (JAK1) inhibitor was effective in Phase 3 studies of active RA in patients (pts) with inadequate…
  • Abstract Number: 660 • 2018 ACR/ARHP Annual Meeting

    Progression of Radiographic Sacroiliitis in Patients with Axial Spondyloarthritis from the Assessment of Spondyloarthritis International Society Cohort on Central Reading – Five-Year Data

    Mikhail Protopopov1, Fabian Proft1, Alexandre Sepriano2,3, Robert B.M. Landewé4,5, Désirée van der Heijde2, Joachim Sieper1, Martin Rudwaleit6,7 and Denis Poddubnyy1,8, 1Charité Universitätsmedizin Berlin, Berlin, Germany, 2Leiden University Medical Center, Leiden, Netherlands, 3Rheumatology, NOVA Medical School, Universidade Nova de Lisboa, Lisbon, Portugal, 4Zuyderland Medical Center, Heerlen, Netherlands, 5Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands, 6Charité Universitätsmeidzin Berlin, Berlin, Germany, 7Rheumatology, Klinikum Bielefeld Rosenhöhe, Berlin, Germany, 8German Rheumatism Research Centre, Berlin, Germany

    Background/Purpose: It is known that radiographic progression of sacroiliitis in axial spondyloarthritis (axSpA) is quite slow, with only few predictors of such progression identified. An…
  • Abstract Number: 863 • 2018 ACR/ARHP Annual Meeting

    Combining Cardiac Magnetic Resonance and Right Heart Catheterization to Evaluate Right Ventricular Function for the Prognosis Prediction in Patients with Connective Tissue Diseases and Pulmonary Hypertension

    Nobuya Abe1, Masaru Kato2, Hiroyuki Nakamura2, Atsushi Noguchi2, Yuichiro Fujieda2, Kenji Oku2, Toshiyuki Bohgaki2, Olga Amengual2, Shinsuke Yasuda2 and Tatsuya Atsumi2, 1Department of Rheumatology, Endocrinology and Nephrology, Graduate School of Medicine, Hokkaido University, Sapporo, Japan, 2Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan

    Background/Purpose: Pulmonary arterial hypertension associated with connective tissue diseases (CTD-PAH), particularly PAH associated with systemic sclerosis (SSc-PAH), has a poor prognosis compared with other PAH.…
  • Abstract Number: 1502 • 2018 ACR/ARHP Annual Meeting

    Predicting Response to Methotrexate Therapy in New-Onset RA: No Value of Adding Protein Biomarkers to Clinical Predictors

    Xavier M Teitsma1, Johannes W. G. Jacobs2, Pascal HP de Jong3, JMW Hazes3, Angelique EAM Weel3,4, Paco MJ Welsing1, Attila Pethö-Schramm5, Michelle EA Borm6, Jacob van Laar1, Johannes W. J. Bijlsma7 and Floris PJG Lafeber8, 1Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands, Utrecht, Netherlands, 2Rheumatolgy & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 3Rheumatology, Erasmus Medical Center Rotterdam, Rotterdam, Netherlands, 4Rheumatology, Maastad Hospital, Rotterdam, Netherlands, 5F. Hoffmann-La Roche, Basel, Switzerland, 6Roche Nederland BV, Woerden, Netherlands, 7Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 8Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands

    Background/Purpose: We previously identified higher disease activity score assessing 28 joints (DAS28) at baseline, current smoking and no alcohol consumption as clinical predictors for inadequate…
  • Abstract Number: 1718 • 2018 ACR/ARHP Annual Meeting

    Skin Gene Expression Profiling Predicts Longitudinal Modified Rodnan Skin Score Change

    Chase Correia1, Mary A. Carns2, Kathleen Aren2, Monique Hinchcliff3 and J. Matthew Mahoney4, 1Rheumatology, Northwestern Feinberg School of Medicine, Chicago, IL, 2Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, 3Rheumatology, Northwestern University, Chicago, IL, 4Neurological Sciences, University of Vermont College of Medicine, Burlington, VT

    Background/Purpose: Systemic sclerosis (SSc) causes varying degrees of skin fibrosis with varying trajectory. Extent of skin involvement is measured by the modified Rodnan skin score…
  • Abstract Number: 1749 • 2018 ACR/ARHP Annual Meeting

    Long-Term Renal Outcome in Pulmonary-Limited Microscopic Polyangiitis

    Hironari Hanaoka, Harunobu Iida, Tomofumi Kiyokawa, Yukiko Takakuwa and Kimito Kawahata, Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan

    Background/Purpose: Patients with pulmonary-renal or renal-limited microscopic polyangiitis (MPA) frequently manifested with rapidly progressive glomerular nephritis resulting in chronic renal failure if clinical response to…
  • Abstract Number: 1885 • 2018 ACR/ARHP Annual Meeting

    Long-Term Outcome and Prognostic Factors of Complications in Thromboangiitis Obliterans (Buerger’s disease): A Multicenter Study of 224 Patients

    Alexandre LE JONCOUR1, Simon Soudet2, Axelle Dupont3, Olivier Espitia4, Fabien Koskas5, Philippe Cluzel6, Pierre-Yves Hatron2, Joseph Emmerich7, Patrice Cacoub1, Matthieu Resche-Rigon3, Marc Lambert2 and David Saadoun1, 1Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France; INSERM, UMR_S 959, F-75013, Paris, France; CNRS, FRE3632, F-75005, Paris, France; AP-HP, Groupe Hospitalier Pitié, Paris, France, 2Département de Médecine Interne et Immunologie Clinique, CHU Lille, F-59000 Lille, France, Centre National de Référence des Maladies Autoimmunes et Systémiques Rares (Sclérodermie), France, Lille, France, 33Service de Biostatistique et Information médicale, Hôpital Saint-Louis, APHP, Paris, France, Paris, France, 4Département de Médecine interne, CHU de Nantes, France, Nantes, France, 5Service de chirurgie vasculaire, Groupe Hospitalier Pitié-Salpétrière, Paris, France, Paris, France, 6Service d’Imagerie Cardiovasculaire, Institut de cardiologie, Groupe Hospitalier Pitié-Salpétrière, Paris, France, Paris, France, 7Department of Vascular Medicine and Cardiology, University Hospital Hotel Dieu, University Paris-Descartes, Paris, France, Paris, France

    Background/Purpose: Data regarding long term outcome of patients with thromboangiitis obliterans (TAO) are lacking and most series come from India and Japan. We assess long-term…
  • Abstract Number: 1929 • 2018 ACR/ARHP Annual Meeting

    The Neutrophil-Lymphocyte Ratio in Newly Diagnosed Rheumatoid Arthritis and Its Ability to Predict Treatment Failure

    Daniel Boulos1, Robert Metcalf2, Susanna Proudman3 and Ian Wicks4, 1Rheumatology, Royal Melbourne Hospital, Melbourne, Melbourne, Australia, 2Rheumatology, Royal Adelaide Hospital, Adelaide, Adelaide, Australia, 3Royal Adelaide Hospital, Rheumatology Unit and University of Adelaide, Discipline of Medicine, Adelaide, Australia, 4Wicks Lab, Walter and Eliza Hall Institute, Melbourne, Australia

    Background/Purpose: To assess whether the neutrophil-lymphocyte ratio (NLR) can predict those who require disease modifying therapy escalation and hence progression in rheumatoid arthritis (RA). Methods:…
  • Abstract Number: 2781 • 2018 ACR/ARHP Annual Meeting

    Long Term Follow-up Results of Takayasu Arteritis Cohort: A Tertiary-Single Center Study

    Sema Kaymaz Tahra1, Fatma Alibaz-Oner1 and Haner Direskeneli2, 1Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, 2Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey

    Background/Purpose: To assess the clinical characteristics and long term follow-up outcomes of patients with Takayasu’s arteritis (TAK) in a tertiary referral center. Methods: In this…
  • Abstract Number: 2936 • 2018 ACR/ARHP Annual Meeting

    Esophageal Erosion Predicts Progression of Lung Disease in Patients with Systemic Sclerosis

    Silvia Laura Bosello1, Enrico De Lorenzis1, Gerlando Natalello2, Giovanni Battista Canestrari1, Laura Gigante1, Lucrezia Verardi1, Ludovica Berardini3 and Elisa Gremese1, 1Division of Rheumatology, Fondazione Policlinico Universitario A.Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy, 2Division of Rhematology, Fondazione Policlinico Universitario A.Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy, 3Division of Respiratory Medicine, Fondazione Policlinico Universitario A.Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy

    Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in Systemic Sclerosis (SSc) but its pathogenesis is not fully understood. Esophageal disease is…
  • Abstract Number: 1389 • 2017 ACR/ARHP Annual Meeting

    Serum Progranulin Antibodies (PGRN-abs) in Rheumatoid Arthritis Patients Being Negative for RF-IgM and ACCP-IgG

    Gunter Assmann1, Silke Zinke2, Moritz Gerling3, Natalie Fadle3, Klaus Dieter Preuss3, Michael Pfreundschuh3 and Lorenz Thurner3, 1Medicine I, University Medical School of Saarland, 66424, Germany, 2Rheumapraxis, Rheumatology Center Berlin - Lichtenberg, Berlin, Germany, 3Medicine I, Jose Carreras Center, University of Saarland, Homburg, Germany

    Background/Purpose: Until recently, most research on progranulin (PGRN) had been focused on its role in neurogenerative diseases as frontotemporal dementia. After the detection of elevated…
  • Abstract Number: 1393 • 2017 ACR/ARHP Annual Meeting

    Patient Characteristics, Treatment Strategy or Investigator Effect: An Analysis of Factors Driving Variation in Outcomes in Early Rheumatoid Arthritis

    Cheryl Barnabe1, Orit Schieir2, Glen Hazlewood1, Susan J. Bartlett3, Carol A Hitchon4, Janet E. Pope5, Gilles Boire6, Edward C. Keystone7, Diane Tin8, B Haraoui9, Vivian P. Bykerk10 and Carter Thorne11, 1Division of Rheumatology, University of Calgary, Calgary, AB, Canada, 2Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, 3Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, 4University of Manitoba, Winnipeg, MB, Canada, 5Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, 6Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, 7University of Toronto, Toronto, ON, Canada, 8The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, 9Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, 102-005, Mt Sinai Hospital, Toronto, ON, Canada, 11University of Toronto, Newmarket, ON, Canada

    Background/Purpose: Outcomes in ERA are largely thought to reflect individual prognostic factors and treatment strategy employed. We hypothesize that an additional factor may be the…
  • Abstract Number: 2022 • 2017 ACR/ARHP Annual Meeting

    Diagnostic and Prognostic VALUE of Salivary GLAND Ultrasonography in Primary Sjögren’s Syndrome:  a Preliminary Study

    Maria Pascual1, Mercè López1, Joan Miquel Nolla2, Javier Narváez3, helena borrell1 and Carmen Moragues4, 1DEPARMENT OF RHEUMATOLOGY, HOSPITAL UNIVERSITARI DE BELLVITGE, BARCELONA, Spain, 2Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 3Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, 4DEPARMENT OF RHEUMATOLOGY, HOSPITAL UNIVERSITARI DE BELLVITGE, barc+, Spain

    Background/Purpose: In recent years, salivary gland ultrasonography (SGUS) has emerged as a promising tool for the diagnosis and prognostic stratification of patiens with primary Sjögren’s…
  • « Previous Page
  • 1
  • …
  • 15
  • 16
  • 17
  • 18
  • 19
  • …
  • 21
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology